Afanat is used to treatment of non-small cell lung carcinoma (NSCLC). It becomes to the tyrosine kinase inhibitor family of the drug. It is taken by mouth. It is primarily used to treat cases of NSCLC that harbor variation inthe epidermal growth factor receptor (EGFR) chromosome. Afatinib is an effective and selective, irreversible ErbBfamily blocker. Afatinib covalently binds to and irreversibly blocks indicating from all homo and heterodimers formed by the ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4. fatinib covalently binds to the kinase rule of EGFR (ErbB1), HER2 (ErbB2), andHER4 (ErbB4) and irreversibly inhibits tyrosine kinase autophosphorylation, resulting in the down-regulation of ErbB in.
non-small cell lung carcinoma